

NICE TA Compliance

Calderdale Clinical Commissioning Group (CCG)

The technology appraisals listed on the following sheets as approved/funded by the CCG, are approved strictly in line with the conditions set out in the relevant NICE Technology Appraisal (TA). Use of drugs, devices and procedures outside of the scope of NICE TAs is strictly in line with CCG commissioning policies or by prior approval through individual funding requests only.

NICE (the National Institute for Health and Care Excellence) issues these guidelines after full consultation with experts within the NHS, in the expectation that the guidance is then followed by relevant NHS organisations such as hospitals and CCGs.

The TAs are presented in a table, with the most recent TA at the top of the page and then presented in descending order. By clicking on the title of the TA you will be linked automatically to the NICE website and the relevant guidance. The next two state whether or not the CCG supports the guidance with appropriate funding. If not, the final column explains why. For example, NHS England is responsible for funding cancer treatments rather than CCGs.

As new NICE TAs are published, this table will be updated.

Date Updated: May 2017

NICE TA 2017-18

| TA Number | TA Subject | Classification (Drug/Device/Pro cedure/Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|-----------|---|---|-----------------------------------|---|-------------------------------|
| TA433 | Apremilast for treating active psoriatic arthritis | Drug | Yes | Yes | |
| TA434 | Elotuzumab for previously treated multiple myeloma (terminated appraisal) | Drug | <u>No</u> | <u>N/A</u> | Responsibility of NHS England |
| TA435 | Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | Drug | <u>No</u> | <u>N/A</u> | Responsibility of NHS England |
| TA436 | Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | Drug | <u>No</u> | <u>N/A</u> | Responsibility of NHS England |

| TA Number | TA Subject | Classification (Drug/Device/Pro cedure/Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|-----------------------|---|---|-----------------------------------|---|-------------------------------|
| TA437 | Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | Drug | <u>No</u> | <u>N/A</u> | Responsibility of NHS England |
| TA438 | Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | Drug | <u>No</u> | <u>N/A</u> | Responsibility of NHS England |
| TA439 | Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | Drug | <u>No</u> | <u>N/A</u> | Responsibility of NHS England |
| TA432 | Everolimus for advanced renal cell carcinoma after previous treatment | Drug | No | N/A | Responsibility of NHS England |

NICE TAs 2016-17

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------------|---|------------------------|
| Osimertinib for treating locally advanced or metastatic EGFR T790M mutationpositive non-small-cell lung cancer (TA416)(Oct 16) | Drug | no | N/A | responsibility of NHSE |
| Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)(Oct 16) | Drug | yes | yes | |
| Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)(Oct 16) | Drug | no | N/A | responsibility of NHSE |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------------|---|------------------------|
| Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)(Oct 16) | Drug | no | N/A | responsibility of NHSE |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (replaces TA376) (TA412)(Sept 16) | Drug | no | N/A | responsibility of NHSE |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)(Sept 16) | Drug | no | N/A | responsibility of NHSE |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------------|---|------------------------|
| Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)(Sept 16) | Drug | no | N/A | responsibility of NHSE |
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)(Sept 16) | Drug | yes | Yes | |
| Pegaspargase for treating acute lymphoblastic leukaemia (TA408)(Sept 16) | Drug | no | N/A | responsibility of NHSE |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------------|---|-------------------------------|
| Secukinumab for active ankylosing spondylitis after treatment with nonsteroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407) (Sept 16) | Drug | yes | Yes | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced nonsmall-cell lung cancer (TA406)(Sept 16) | Drug | no | N/A | responsibility of NHSE |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)(Aug 16) | Drug | no | na | responsibility of NHSE |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------------|---|---|
| Degarelix for treating advanced hormone-dependent prostate cancer (TA404) (Aug 16) | Drug | yes | yes | |
| Ramucirumab for previously treated locally advanced or metastatic non-smallcell lung cancer (TA403) (Aug 16) | Drug | no | na | responsibility of NHSE (not recommended) |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402) (Aug 16) | Drug | no | na | responsibility of NHSE |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------------|---|--|
| Bosutinib for previously treated chronic myeloid leukaemia (TA401) (Aug 16) | Drug | no | na | responsibility of NHSE |
| Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400) (Jul 16) | Drug | no | na | responsibility of NHSE |
| Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399) (Jul 16) | Drug | no | na | responsibility of NHSE (not recommended) |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------------|---|--|
| Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398) (Jul 16) | Drug | no | na | responsibility of NHSE (not recommended) |
| Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397) (Jun 16) | Drug | no | NA | responsibility of NHSE |
| Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)(Jun 16) | Drug | no | NA | responsibility of NHSE |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------------|---|------------------------|
| Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)(Jun 16) | Drug | no | NA | responsibility of NHSE |
| Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)(Jun 16) | Drug | yes | yes | |
| Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393) (june 16) | Drug | yes | yes | |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------------|---|------------------------|
| Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392) (May 16) | Drug | no | NA | Responsibility of NHSE |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391) (May 16 updated Aug 16) | Drug | no | NA | responsibility of NHSE |
| Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)(May 16) | Drug | yes | yes | |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------------|---|---|
| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)(Apr 16) | Drug | no | NA | responsibility of NHSE (Replaces TA91 and TA222) |
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)(Apr 16) | Drug | yes | yes | |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------------|---|------------------------|
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)(Apr 16 updated July 16) | Drug | no | NA | Responsibility of NHSE |

NICE TAs 2015-16

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|--|-------------------------------|
| Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)(Mar 16) | Drug | no | NA | Responsibility of NHSE |
| Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)(Feb 16) | Drug | yes | yes | |
| Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)(Feb 16) | Drug | no | No | Responsible for NHSE |
| TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)(Feb 16) | Drug | yes | yes | |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|--|-------------------------------|
| Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)(TA 382)(Jan 16) | Drug | yes | No | Terminated appraisal |
| Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)(Jan 16) | Drug | no | No | Responsibility of NHSE |
| Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380) (Jan 16) | Drug | No | No | Responsibility of NHSE |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|--|---|
| Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380) (Jan 16) | Drug | no | No | Responsibility of NHSE |
| Nintedanib for treating idiopathic pulmonary fibrosis (TA379) (Jan 16) | Drug | yes | No | Responsibility of NHSE |
| Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378) (Jan 16) | Drug | no | NA | Responsibility of NHSE (not recommended) |
| Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)(Jan 16) | Drug | no | N/A | Responsibility of NHSE |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------|--|-------------------------------|
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastase (TA376)(Jan 16) | Drug | no | N/A | Responsibility of NHSE |
| Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375) (Jan 15) | Drug | yes | Yes | |
| Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374) (Dec 15) | Drug | no | n/a | Responsibility of NHSE |
| Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373) (Dec 15) | Drug | no | NA | Responsibility of NHSE |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|--|---|
| Apremilast for treating active psoriatic arthritis (TA372) (Dec 15) | Drug | Yes | No | Not recommended |
| Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371) (Dec 15) | Drug | No | N/A | Responsibility of NHSE (not recommended) |
| Bortezomib for previously untreated mantle cell lymphoma (Dec 15) | Drug | No | N/A | Responsibility of NHSE |
| Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369) (Dec 15) | Drug | Yes | Yes | |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------|--|-------------------------------|
| Apremilast for treating moderate to severe plaque psoriasis (TA368) (Nov 15) | Drug | yes | No | Not recommended |
| Vortioxetine for treating major depressive episodes (TA367) (Nov 15) | Drug | Yes | Yes | |
| Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366) (Nov 15) | Drug | No | N/A | Responsibility of NHSE |
| Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)(Nov 15) | Drug | No | N/A | Responsibility of NHSE |
| Daclatasvir for treating chronic hepatitis C (TA364) | Drug | No | N/A | Responsibility of NHSE |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------|--|---|
| Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363) | Drug | No | N/A | Responsibility of NHSE |
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA 362) | Drug | No | N/A | Responsibility of NHSE (terminated appraisal) |
| Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361) | Drug | No | NA | Responsibility of NHSE (terminated appraisal) |
| Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360) | Drug | No | N/A | Responsibility of NHSE |
| Idelalisib for treating chronic lymphocytic leukaemia (TA359) | Drug | No | N/A | Responsibility of NHSE |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|--|---|
| Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358) | Drug | Yes | Yes | |
| Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357) | Drug | No | N/A | Responsibility of NHSE |
| Ruxolitinib for treating polycythaemia vera (terminated appraisal)(TA356)(Sept15) | Drug | N/A | N/A | TERMINATED APPRAISAL - NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera that is resistant to hydroxycarbamide or for people who cannot tolerate hydroxycarbamide because no evidence submission was received from Novartis Pharmaceuticals for the technology. |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------|--|---|
| Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)(Sept15) | Drug | Yes | Yes | |
| Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)(Aug15) | Drug | Yes | Yes | |
| Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)(TA353)(Aug15) | Drug | N/A | N/A | TERMINATED APPRAISAL - NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer because no evidence submission was received from Roche Products for the technology |
| Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)(Aug15) | Drug | Yes | Yes | |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|--|--|
| Cangrelor for reducing atherothrombotic events in people undergoing PCI or awaiting surgery requiring interruption of anti-platelet therapy (TA351)(July15) | Drug | N/A | N/A | TERMINATED APPRAISAL - NICE is unable to make a recommendation about the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy because no evidence submission was received from The |
| Secukinumab for treating moderate to severe plaque psoriasis (TA350)(July15) | Drug | Yes | Yes | |
| Dexamethasone intravitreal implant for diabetic macular oedema (TA349)(July15) | Drug | Yes | Yes | |
| Everolimus for preventing organ rejection in liver transplant (TA348)(July15) | Drug | No | N/A | Responsibility of NHSE (Everolimus is not recommended within its marketing authorisation for preventing organ rejection in people having a liver transplant) |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|--|------------------------|
| Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small cell lung cancer (TA347)(July15) | Drug | No | N/A | Responsibility of NHSE |
| Aflibercept for treating diabetic macular oedema (TA346)(July15) | Drug | Yes | Yes | |
| Naloxegol for treating opioid induced constipation (TA345)(July15) | Drug | Yes | Yes | |
| Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344) (Jun15) | Drug | No | N/A | Responsibility of NHSE |
| Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343) (Jun15) | Drug | No | N/A | Responsibility of NHSE |
| Vedolizumab for treating moderately to severely active ulcerative colitis (TA342) (Jun15) | Drug | Yes | Yes | |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|--|------------------------|
| Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341) (Jun15) | Drug | Yes | Yes | |
| Ustekinumab for treating active psoriatic arthritis (TA340) (Jun15) | Drug | Yes | Yes | |
| Omalizumab for previously treated chronic spontaneous urticaria (TA339) (Jun15) | Drug | No | N/A | Responsibility of NHSE |

NICE TAs 2014-15

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338) (Mar15) | Drug | No | N/A | Responsibility of NHSE (Not routinely funded in line with NICE recommendations) |
| Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337) (Mar15) | Drug | Yes | Yes | |
| Empagliflozin in combination therapy for treating type 2 diabetes (TA336) (Mar15) | Drug | Yes | Yes | |
| Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335) (Mar15) | Drug | Yes | Yes | |
| Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334) (Feb15) | Drug | No | N/A | Responsibility of NHSE (Not routinely funded: terminated appraisal) |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|--|
| Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333) (Feb15) | Drug | No | N/A | Responsibility of NHSE |
| Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA332) (Feb15) | Drug | No | N/A | Responsibility of NHSE (Not routinely funded in line with NICE recommendations) |
| Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA 331) (Feb15) | Drug | No | N/A | Responsibility of NHSE |
| Sofosbuvir for treating chronic hepatitis C (TA330) (Feb15) | Drug | No | N/A | Responsibility of NHSE |
| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329) (Feb15) | Drug | Yes | Yes | Includes a review of TA140 and TA262 |
| Eculizumab for treating atypical haemolytic uraemic syndrome (HST1) (Jan15) | Drug | No | N/A | Responsibility of NHSE (specialised commissioning) |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328) (Dec14) | Drug | No | N/A | Responsibility of NHSE (Not routinely funded: terminated appraisal) |
| Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327) (Dec14) | Drug | Yes | Yes | |
| Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326) (Nov14) | Drug | No | N/A | Responsibility of NHSE (Review of NICE TA196) |
| Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325) (Nov14) | Drug | Yes | Yes | |
| Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324) (Nov14) | Device | Yes | Yes | Part review of TA8 |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|-------------------------------|
| Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323) (Nov14) | Drug | Yes | Yes | Includes review of TA142 |
| Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321) (Oct14) | Drug | No | N/A | Responsibility of NHS England |
| Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322) (Sep14) | Drug | No | N/A | Responsibility of NHS England |
| Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320) (Aug14) | Drug | No | N/A | Responsibility of NHS England |
| Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319) (Jul14) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|--------------------------------------|
| Lubiprostone for treating chronic idiopathic constipation (TA318) (Jul14) | Drug | Yes | Yes | |
| Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317) (Jul14) | Drug | Yes | Yes | Review of NICE TA182 |
| Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316) (Jul14) | Drug | No | N/A | Responsibility of NHS England |
| Canagliflozin in combination therapy for treating type 2 diabetes (TA315) (Jun14) | Drug | Yes | Yes | |
| Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120) (TA314) (Jun14) | Device | Yes | Yes | |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Psoriatic arthritis (active) - ustekinumab (TA313) (May 14) | Drug | Yes | N/A | Not routinely funded, in line with NICE recommendation. Ustekinumab is not recommended for active psoriatic arthritis when treatment with non-biological disease-modifying antirheumatic drugs (or DMARDs) has not worked well enough. |
| Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312) (May14) | Drug | No | N/A | Responsibility of NHS England |
| Multiple myeloma - bortezomib (induction therapy) (TA311) (Apr14) | Drug | No | N/A | Responsibility of NHS England |
| Lung cancer (non small cell, EGFR mutation positive) - afatinib (TA310) (Apr14) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Lung cancer (non small cell, non squamous) - pemetrexed (TA309) (Apr14) | Drug | No | N/A | <p>Responsibility of NHS England. Pemetrexed is not recommended as maintenance treatment for people with locally advanced or metastatic non-squamous non-small-cell lung cancer after therapy with pemetrexed and cisplatin.</p> |

NICE TAs 2013-14

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|---|
| Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308) | Drug | No | N/A | Responsibility of NHS England |
| Colorectal cancer (metastatic) - aflibercept (TA307) | Drug | No | N/A | Responsibility of NHS England |
| Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306) (Feb'14) | Drug | No | N/A | Responsibility of NHS England |
| Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305) (Feb'14) | Drug | Yes | Yes | |
| Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44) (TA304) (Feb'14) | Procedure | Yes | Yes | |
| Multiple sclerosis (relapsing) - teriflunomide (TA303) (Jan'14) | Drug | No | N/A | Responsibility of NHS England |
| Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302) (Nov'13) | Drug | Yes | N/A | Terminated Appraisal. Not routinely funded in line with NICE recommendation. |
| Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301) (Nov'13) | Drug | Yes | Yes | |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Hepatitis C (children and young people) - peginterferon alfa and ribavirin (TA300) (Nov'13) | Drug | No | N/A | Responsibility of NHS England |
| Bosutinib for previously treated chronic myeloid leukaemia (TA299) (Nov'13) | Drug | No | N/A | Responsibility of NHS England. NICE does not recommend bosutinib for previously treated chronic myeloid leukaemia |
| Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298) (Nov'13) | Drug | Yes | Yes | |
| Vitreomacular traction - ocriplasmin (TA297) (October '13) | Drug | Yes | Yes | |
| Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (TA296) (September '13) | Drug | No | N/A | Responsibility of NHS England. NICE does not recommend crizotinib for people with a type of advanced non-small-cell lung cancer that is 'ALK-positive' and has been treated before. |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|---|
| Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295) (August '13) | Drug | No | N/A | <p>Responsibility of NHS England. Not routinely funded in line with NICE recommendation. NICE does not recommend the use of everolimus, in combination with exemestane, for treating postmenopausal women with advanced HER2 negative hormone receptor-positive breast cancer that has recurred or progressed following treatment with a non-steroidal aromatase inhibitor.</p> |
| Macular degeneration (wet age-related) aflibercept (TA294) (July '13) | Drug | Yes | Yes | |
| Thrombocytopenic purpura - eltrombopag (TA293) (July '13) | Drug | Yes | Yes | |
| Bipolar disorder (children) - aripiprazole (TA292) (July '13) | Drug | Yes | Yes | |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|---|
| Gout (tophaceous, severe debilitating, chronic) - pegloticase (TA291) (June '13) | Drug | No | N/A | Not routinely funded in line with NICE recommendation. NICE does not recommend pegloticase for people who have severe, chronic gout with tophi who have either tried oral gout drugs and still have high uric acid levels, or cannot take oral gout drugs. |
| Overactive bladder - mirabegron (TA290) (June '13) | Drug | Yes | Yes | |
| Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (TA289) (June'13) | Drug | No | N/A | Not routinely funded in line with NICE recommendation. NICE does not recommend ruxolitinib for people with an enlarged spleen or symptoms from myelofibrosis. |
| Type 2 diabetes - Dapagliflozin combination therapy (TA288) (June '13) | Drug | Yes | Yes | |
| Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287) (June '13) | Drug | Yes | Yes | |
| Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286) (May'13) | Drug | No | N/A | Terminated Appraisal. Not routinely funded in line with NICE recommendation. |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|---|
| Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285) (May'13) | Drug | No | N/A | Responsibility of NHS England. Bevacizumab in combination with gemcitabine and carboplatin is not recommended for treating people with first recurrence of platinum-sensitive advanced ovarian cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. |
| Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284) (May'13) | Drug | No | N/A | Responsibility of NHS England. NICE does not recommend bevacizumab, given with paclitaxel and carboplatin, as first-line treatment for advanced ovarian cancer (including fallopian tube and primary peritoneal cancer). |
| Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283) (May'13) | Drug | Yes | Yes | |
| Pirfenidone for treating idiopathic pulmonary fibrosis (TA282) (Apr'13) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Gout - canakinumab (terminated appraisal) (TA281) (Apr'13) | Drug | No | N/A | Terminated Appraisal. Not routinely funded in line with NICE recommendation. |
| Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234) (TA280) (Apr'13) | Drug | Yes | Yes | Replaces NICE TA234 |
| Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures (TA279) (Apr'13) | Procedure | Yes | Yes | Procedure (level 2 or below) commissioned by CCG. Specialist spinal surgery commissioned by NHS E |
| Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201) (TA278) (Apr'13) | Drug | No | N/A | Responsibility of NHS England |

NICE TAs 2012-13

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------|--|---|
| Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277) | Drug | No | N/A | Terminated Appraisal. Not routinely funded in line with NICE recommendation. |
| Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276) | Drug | No | N/A | Responsibility of NHS England |
| Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275) | Drug | Yes | Yes | |
| Macular oedema (diabetic) - ranibizumab (TA274) | Drug | Yes | Yes | |
| Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273) | Drug | No | N/A | Terminated Appraisal. Not routinely funded in line with NICE recommendation. |
| Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272) | Drug | No | N/A | Responsibility of NHS England |
| Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271) | Drug | Yes | N/A | Not routinely funded in line with NICE recommendation. |
| Leukaemia (acute myeloid) - decitabine (terminated appraisal) (TA270) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------|--|---|
| Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269) | Drug | No | N/A | Responsibility of NHS England |
| Melanoma (stage III or IV) - ipilimumab (TA268) | Drug | No | N/A | Responsibility of NHS England |
| Chronic heart failure - ivabradine (TA267) | Drug | Yes | Yes | |
| Cystic fibrosis - mannitol dry powder for inhalation (TA266) | Drug | No | N/A | Responsibility of NHS England |
| Bone metastases from solid tumours - denosumab (TA265) | Drug | No | N/A | Responsibility of NHS England |
| Stroke (acute, ischaemic) - alteplase (TA264) | Drug | Yes | Yes | Included in PbR tariff |
| Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263) | Drug | No | N/A | Responsibility of NHS England |
| Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal) (TA262) | Drug | Yes | No | Terminated Appraisal. Not routinely funded in line with NICE recommendation |
| Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban (TA261) | Drug | Yes | Yes | |
| Migraine (chronic) - botulinum toxin type A (TA260) | Drug | Yes | Yes | |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------|--|-------------------------------|
| Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy) (TA259) | Drug | No | N/A | Responsibility of NHS England |
| Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258) | Drug | No | N/A | Responsibility of NHS England |
| Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257) | Drug | No | N/A | Responsibility of NHS England |
| Atrial fibrillation (stroke prevention) - rivaroxaban (TA256) | Drug | Yes | Yes | |
| Prostate cancer - cabazitaxel (TA255) | Drug | No | N/A | Responsibility of NHS England |
| Multiple sclerosis (relapsing-remitting) - fingolimod (TA254) | Drug | No | N/A | Responsibility of NHS England |
| Hepatitis C (genotype 1) - boceprevir (TA253) | Drug | No | N/A | Responsibility of NHS England |
| Hepatitis C (genotype 1) - telaprevir (TA252) | Drug | No | N/A | Responsibility of NHS England |
| Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib (TA251) | Drug | No | N/A | Responsibility of NHS England |
| Breast cancer (advanced) - eribulin (TA250) | Drug | No | N/A | Responsibility of NHS England |

NICE TAs 2011-12

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Atrial fibrillation - dabigatran etexilate (TA249) | Drug | Yes | Yes | |
| Diabetes (type 2) - exenatide (prolonged release) (TA248) | Drug | Yes | Yes | |
| Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247) | Drug | Yes | Yes | |
| Venom anaphylaxis - immunotherapy pharmlagen (TA246) | Drug | No | N/A | Responsibility of NHS England |
| Venous thromboembolism - apixaban (hip and knee surgery) (TA245) | Drug | Yes | Yes | Included in PbR tariff for procedures |
| Chronic obstructive pulmonary disease - roflumilast (TA244) | Drug | Yes | Yes | |
| Follicular lymphoma - rituximab (review) (TA243) | Drug | No | N/A | Responsibility of NHS England |
| Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) (TA242) | Drug | No | N/A | Responsibility of NHS England |
| Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) (TA241) | Drug | No | N/A | Responsibility of NHS England |
| Colorectal cancer (metastatic) - panitumumab (terminated appraisal) (TA240) | Drug | No | N/A | Responsibility of NHS England |
| Breast cancer (metastatic) - fulvestrant (TA239) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238) | Drug | Yes | Yes | |
| Macular oedema (diabetic) - ranibizumab (TA237) | Drug | Yes | N/A | Replaced by TA274 |
| Acute coronary syndromes - ticagrelor (TA236) | Drug | Yes | Yes | |
| Osteosarcoma - mifamurtide (TA235) | Drug | No | N/A | Responsibility of NHS England |
| Rheumatoid arthritis - abatacept (2nd line) (TA234) | Drug | Yes | No | Not routinely funded in line with NICE recommendation (superseded by TA280) |
| Ankylosing spondylitis - golimumab (TA233) | Drug | Yes | Yes | |
| Epilepsy (partial) - retigabine (adjuvant) (TA232) | Drug | Yes | Yes | |
| Depression - agomelatine (terminated appraisal) (TA231) | Drug | Yes | No | Not routinely funded in line with NICE recommendation |
| Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230) | Drug | Yes | Yes | |
| Macular oedema (retinal vein occlusion) - dexamethasone (TA229) | Drug | Yes | Yes | |
| Multiple myeloma (first line) - bortezomib and thalidomide (TA228) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) (TA227) | Drug | No | N/A | Responsibility of NHS England |
| Lymphoma (follicular non-Hodgkin's) - rituximab (TA226) | Drug | No | N/A | Responsibility of NHS England |
| Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225) | Drug | Yes | Yes | |
| Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal) (TA224) | Drug | Yes | No | Terminated Appraisal. Not routinely funded in line with NICE recommendation. |
| Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate (TA223) | Drug | Yes | Yes | |
| Ovarian cancer (relapsed) - trabectedin (TA222) | Drug | No | N/A | |
| Thrombocytopenic purpura - romiplostim (TA221) | Drug | Yes | Yes | |
| Psoriatic arthritis - golimumab (TA220) | Drug | Yes | Yes | |
| Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219) | Drug | No | N/A | Responsibility of NHS England |

NICE TAs 2010-11

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|--------------------------------------|
| Myelodysplastic syndromes - azacitidine (TA218) | Drug | No | N/A | Responsibility of NHS England |
| Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217) | Drug | Yes | Yes | |
| Leukaemia (lymphocytic) - bendamustine (TA216) | Drug | No | N/A | Responsibility of NHS England |
| Renal cell carcinoma (first line metastatic) - pazopanib (TA215) | Drug | No | N/A | Responsibility of NHS England |
| Breast cancer - bevacizumab (in combination with a taxane) (TA214) | Drug | No | N/A | Responsibility of NHS England |
| Schizophrenia - aripiprazole (TA213) | Drug | Yes | Yes | |
| Colorectal cancer (metastatic) - bevacizumab (TA212) | Drug | No | N/A | Responsibility of NHS England |
| Constipation (women) - prucalopride (TA211) | Drug | Yes | Yes | |
| Vascular disease - clopidogrel and dipyridamole (TA210) | Drug | Yes | Yes | |
| Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) | Drug | No | N/A | Responsibility of NHS England |
| Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208) | Drug | No | N/A | Responsibility of NHS England |
| Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) (TA207) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|--------------------------------------|
| Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal) (TA206) | Drug | No | N/A | Responsibility of NHS England |
| Thrombocytopenic purpura - eltrombopag (TA205) | Drug | Yes | Yes | |
| Osteoporotic fractures - denosumab (TA204) | Drug | Yes | Yes | |
| Diabetes (type 2) - liraglutide (TA203) | Drug | Yes | Yes | |
| Chronic lymphocytic leukaemia - ofatumumab (TA202) | Drug | No | N/A | Responsibility of NHS England |
| Asthma (in children) - omalizumab (TA201) | Drug | No | N/A | Responsibility of NHS England |
| Hepatitis C - peginterferon alfa and ribavirin (TA200) | Drug | No | N/A | Responsibility of NHS England |
| Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199) | Drug | Yes | Yes | |
| Atrial fibrillation - dronedarone (TA197) | Drug | Yes | Yes | |
| Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196) | Drug | No | N/A | Responsibility of NHS England |
| Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195) | Drug | Yes | Yes | |
| Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) (TA194) | Drug | No | N/A | Responsibility of NHS England |
| Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device /Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|--------------------------------------|
| Lung cancer (non-small-cell, first line) - gefitinib (TA192) | Drug | No | N/A | Responsibility of NHS England |
| Gastric cancer (advanced) - capecitabine (TA191) | Drug | No | N/A | Responsibility of NHS England |
| Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190) | Drug | No | N/A | Responsibility of NHS England |
| Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) (TA189) | Drug | No | N/A | Responsibility of NHS England |
| Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188) | Drug | Yes | Yes | |
| Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187) | Drug | Yes | Yes | |

NICE TAs 2009-10

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|--------------------------------------|
| Rheumatoid arthritis - certolizumab pegol (TA186) | Drug | Yes | Yes | |
| Soft tissue sarcoma - trabectedin (TA185) | Drug | No | N/A | Responsibility of NHS England |
| Lung cancer (small-cell) - topotecan (TA184) | Drug | No | N/A | Responsibility of NHS England |
| Cervical cancer (recurrent) - topotecan (TA183) | Drug | No | N/A | Responsibility of NHS England |
| Acute coronary syndrome - prasugrel (TA182) | Drug | Yes | Yes | |
| Lung cancer (non-small-cell, first line treatment) - pemetrexed (TA181) | Drug | No | N/A | |
| Psoriasis - ustekinumab (TA180) | Drug | Yes | Yes | |
| Gastrointestinal stromal tumours - sunitinib (TA179) | Drug | No | N/A | Responsibility of NHS England |
| Renal cell carcinoma (TA178) | Drug | No | N/A | Responsibility of NHS England |
| Eczema (chronic) - alitretinoin (TA177) | Drug | Yes | Yes | |
| Colorectal cancer (first line) - cetuximab (TA176) | Drug | No | N/A | Responsibility of NHS England |
| Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) (TA175) | Drug | No | N/A | Responsibility of NHS England |
| Leukaemia (chronic lymphocytic, first line) - rituximab (TA174) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device/ Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|---------------------------------------|
| Hepatitis B - tenofovir disoproxil fumarate (TA173) | Drug | No | N/A | Responsibility of NHS England |
| Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172) | Drug | No | N/A | Responsibility of NHS England |
| Multiple myeloma - lenalidomide (TA171) | Drug | No | N/A | Responsibility of NHS England |
| Venous thromboembolism - rivaroxaban (TA170) | Drug | Yes | Yes | Included in PbR tariff for procedures |

NICE TAs pre April 2009

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|---|
| Renal cell carcinoma - sunitinib (TA169) | Drug | No | N/A | |
| Influenza - zanamivir, amantadine and oseltamivir (review) (TA168) | Drug | Yes | Yes | |
| Abdominal aortic aneurysm - endovascular stent-grafts (TA167) | Procedure | Yes | Yes | |
| Hearing impairment - cochlear implants (TA166) | Device | No | N/A | Responsibility of NHS England |
| Organ preservation (renal) - machine perfusion and static storage (TA165) | Procedure | No | N/A | Responsibility of NHS England |
| Hyperuricaemia - febuxostat (TA164) | Drug | Yes | Yes | |
| Ulcerative colitis (acute exacerbations) - infliximab (TA163) | Drug | Yes | Yes | |
| Lung cancer (non-small-cell) - erlotinib (TA162) | Drug | No | N/A | Responsibility of NHS England |
| Osteoporosis - secondary prevention including strontium ranelate (TA161) | Drug | Yes | Yes | |
| Osteoporosis - primary prevention (TA160) | Drug | Yes | Yes | |
| Pain (chronic neuropathic or ischaemic) - spinal cord stimulation (TA159) | Procedure | Yes | Yes | |
| Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158) | Drug | Yes | N/A | Updated by TA168. Funded in line with TA 168 |
| Venous thromboembolism - dabigatran (TA157) | Drug | Yes | Yes | Included in PbR tariff for procedures |
| Pregnancy (rhesus negative women) - routine anti-D (review) (TA156) | Drug | Yes | Yes | |

| TA Subject | Classification (Drug/Device/Procedure/Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------|--|--|
| Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155) | Drug | Yes | Yes | |
| Hepatitis B - telbivudine (TA154) | Drug | No | N/A | Responsibility of NHS England |
| Hepatitis B - entecavir (TA153) | Drug | No | N/A | Responsibility of NHS England |
| Coronary artery disease - drug-eluting stents (TA152) | Device | Yes | Yes | |
| Diabetes - insulin pump therapy (TA151) | Device | Yes | Yes | |
| Glioma (recurrent) - carmustine implants (terminated appraisal) (TA149) | Drug | No | N/A | Responsibility of NHS England |
| Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) (TA148) | Drug | No | N/A | Responsibility of NHS England |
| Psoriasis - adalimumab (TA146) | Drug | Yes | Yes | |
| Head and neck cancer - cetuximab (TA145) | Drug | No | N/A | Responsibility of NHS England |
| Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143) | Drug | Yes | Yes | |
| Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin (TA142) | Drug | No | N/A | Responsibility of NHS England |
| Ulcerative colitis (subacute manifestations) - infliximab (TA140) | Drug | Yes | No | Not routinely funded in line with NICE TA |
| Sleep apnoea - continuous positive airway pressure (CPAP) (TA139) | Device | Yes | Yes | |

| TA Subject | Classification (Drug/Device/Procedure/Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------|--|---|
| Asthma (in adults) - corticosteroids (TA138) | Drug | Yes | Yes | |
| Lymphoma (follicular non-Hodgkin's) - rituximab (TA137) | Drug | No | N/A | Responsibility of NHS England |
| Structural neuroimaging in first-episode psychosis (TA136) | Procedure | Yes | N/A | Not routinely funded in line with NICE recommendation. |
| Mesothelioma - pemetrexed disodium (TA135) | Drug | No | N/A | Responsibility of NHS England |
| Psoriasis - infliximab (TA134) | Drug | Yes | Yes | |
| Asthma (uncontrolled) - omalizumab (TA133) | Drug | Yes | Yes | |
| Hypercholesterolaemia - ezetimibe (TA132) | Drug | Yes | Yes | |
| Asthma (in children) - corticosteroids (TA131) | Drug | Yes | Yes | |
| Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130) | Drug | Yes | N/A | Responsibility of NHS England |
| Multiple myeloma - bortezomib (TA129) | Drug | No | N/A | Responsibility of NHS England |
| Haemorrhoid - stapled haemorrhoidopexy (TA128) | Procedure | Yes | Yes | |
| Multiple sclerosis - natalizumab (TA127) | Drug | No | N/A | Responsibility of NHS England |
| Lung cancer (non-small-cell) - pemetrexed (TA124) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|---|-----------------------------------|---|--|
| Smoking cessation - varenicline (TA123) | Drug | No | N/A | Commissioned by Public Health/Local Authority |
| Ischaemic stroke (acute) - alteplase (TA122) | Drug | Yes | Yes | |
| Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121) | Drug | No | N/A | Responsibility of NHS England |
| Heart failure - cardiac resynchronisation (TA120) | Procedure | No | N/A | Responsibility of NHS England |
| Leukaemia (lymphocytic) - fludarabine (TA119) | Drug | No | N/A | Responsibility of NHS England |
| Colorectal cancer (metastatic) - bevacizumab and cetuximab (TA118) (partially updated by TA242) | Drug | No | N/A | Responsibility of NHS England |
| Hyperparathyroidism - cinacalcet (TA117) | Drug | Yes | Yes | |
| Breast cancer - gemcitabine (TA116) | Drug | No | N/A | Responsibility of NHS England |
| Drug misuse - naltrexone (TA115) | Drug | No | N/A | Commissioned by Public Health/Local Authority |
| Drug misuse - methadone and buprenorphine (TA114) | Drug | No | N/A | Commissioned by Public Health/Local Authority |
| Breast cancer (early) - hormonal treatments (TA112) | Drug | No | N/A | Responsibility of NHS England |
| Breast cancer (early) - docetaxel (TA109) | Drug | No | N/A | Updated by CG80 Responsibility of NHS England |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|---|
| Breast cancer (early) - paclitaxel (TA108) | Drug | No | N/A | Updated by CG80 Responsibility of NHS England |
| Breast cancer (early) - trastuzumab (TA107) | Drug | No | N/A | Updated by CG80 Responsibility of NHS England |
| Hepatitis C - peginterferon alfa and ribavirin (TA106) | Drug | No | N/A | Responsibility of NHS England |
| Colorectal cancer - laparoscopic surgery (review) (TA105) | Procedure | Yes | Yes | |
| Psoriasis - efalizumab and etanercept (TA103) | Drug | Yes | Yes | |
| Conduct disorder in children - parent-training/education programmes (TA102) | Other | Yes | Yes | |
| Prostate cancer (hormone-refractory) - docetaxel (TA101) | Drug | No | N/A | Responsibility of NHS England |
| Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100) | Drug | No | N/A | Responsibility of NHS England |
| Renal transplantation - immunosuppressive regimens for children and adolescents (TA99) | Drug | No | N/A | Responsibility of NHS England |
| Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (TA98) | Drug | Yes | Yes | |
| Depression and anxiety - computerised cognitive behavioural therapy (CCBT) (TA97) | Other | Yes | Yes | |

| TA Subject | Classification (Drug/Device/Procedure/Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------|--|--|
| Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (TA96) | Drug | No | N/A | Responsibility of NHS England |
| Arrhythmia - implantable cardioverter defibrillators (ICDs) (review) (TA95) | Procedure | No | N/A | Responsibility of NHS England |
| Cardiovascular disease - statins (TA94) | Drug | Yes | Yes | |
| Tooth decay - HealOzone (TA92) | Procedure | No | N/A | Responsibility of NHS England |
| Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (TA91) | Drug | No | N/A | Responsibility of NHS England |
| Bradycardia - dual chamber pacemakers (TA88) | Device | Yes | Yes | Some patients may be funded by NHS England |
| Gastrointestinal stromal tumours - imatinib (TA86) | Drug | No | N/A | Responsibility of NHS England |
| Renal transplantation - immuno-suppressive regimens (adults) (TA85) | Drug | No | N/A | Responsibility of NHS England |
| Hernia - laparoscopic surgery (review) (TA83) | Procedure | Yes | Yes | |
| Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82) | Drug | Yes | Yes | |
| Atopic dermatitis (eczema) - topical steroids (TA81) | Drug | Yes | Yes | |
| Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation (TA78) | Procedure | Yes | Yes | |
| Insomnia - newer hypnotic drugs (TA77) | Drug | Yes | Yes | |

| TA Subject | Classification (Drug/Device/Procedure/Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|--|-----------------------------|--|-------------------------------|
| Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75) | Drug | No | N/A | Responsibility of NHS England |
| Trauma - fluid replacement therapy (TA74) | Other | Yes | Yes | |
| Angina and myocardial infarction - myocardial perfusion scintigraphy (TA73) | Procedure | Yes | Yes | |
| Ischaemic heart disease - coronary artery stents (TA71) | Procedure | No | N/A | Responsibility of NHS England |
| Leukaemia (chronic myeloid) - imatinib (TA70) (partially updated by TA241 and TA251) | Drug | No | N/A | Responsibility of NHS England |
| Cervical cancer - cervical screening (review) (TA69) | Procedure | No | N/A | Responsibility of NHS England |
| Macular degeneration (age-related) - photodynamic therapy (TA68) | Procedure | Yes | Yes | |
| Non-Hodgkin's lymphoma - rituximab (TA65) | Drug | No | N/A | Responsibility of NHS England |
| Growth hormone deficiency (adults) - human growth hormone (TA64) | Drug | Yes | Yes | |
| Colorectal cancer - capecitabine and tegafur uracil (TA61) | Drug | No | N/A | Responsibility of NHS England |
| Diabetes (types 1 and 2) - patient education models (TA60) | Other | Yes | Yes | |
| Electroconvulsive therapy (ECT) (TA59) | Procedure | Yes | Yes | |
| Ovarian cancer - paclitaxel (review) (TA55) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device/Procedure/Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|---|--|-----------------------------|--|--------------------------------------|
| Diabetes (types 1 and 2) - long acting insulin analogues (TA53) | Drug | Yes | Yes | |
| Myocardial infarction - thrombolysis (TA52) | Drug | Yes | Yes | |
| Central venous catheters - ultrasound locating devices (TA49) | Device | Yes | Yes | |
| Renal failure - home versus hospital haemodialysis (TA48) | Procedure | No | N/A | Responsibility of NHS England |
| Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47) (partially updated by CG94) | Drug | Yes | Yes | Funded in line with CG94. |
| Hip disease - metal on metal hip resurfacing (TA44) | Device | Yes | Yes | |
| Asthma (older children) - inhaler devices (TA38) | Device | Yes | Yes | |
| Arthritis (juvenile idiopathic) - etanercept (TA35) | Drug | Yes | Yes | |
| Breast cancer - trastuzumab (TA34) | Drug | No | N/A | Responsibility of NHS England |
| Multiple sclerosis - beta interferon and glatiramer acetate (TA32) | Drug | No | N/A | Responsibility of NHS England |
| Leukaemia (lymphocytic) - fludarabine (TA29) | Drug | No | N/A | Responsibility of NHS England |
| Pancreatic cancer - gemcitabine (TA25) | Drug | No | N/A | Responsibility of NHS England |
| Brain cancer - temozolomide (TA23) | Drug | No | N/A | Responsibility of NHS England |

| TA Subject | Classification (Drug/Device/Procedure/ Other) | Applicable to CCGs (Yes/No) | Funding agreed for treatment in line with Technology Appraisal | Comments |
|--|---|-----------------------------------|---|--|
| Motor neurone disease - riluzole (TA20) | Drug | Yes | Yes | |
| Asthma (children under 5) - inhaler devices (TA10) | Device | Yes | Yes | |
| Hip disease - replacement prostheses (TA2) | Procedure | Yes | Yes | |
| Wisdom teeth - removal (TA1) | Procedure | No | N/A | Responsibility of NHS England |